Biologics Step Therapy: Understanding Fail-First Requirements by Payer
Step therapy is one of the biggest friction points in biologics prior authorization — not because the concept is complicated, but because every payer does it differently. The sequence that satisfies UnitedHealthcare won't necessarily satisfy Aetna. The duration of prior treatment failure that clears Cigna may fall short at a Medicare Advantage plan. Get one detail wrong and the submission comes back denied, costing your patient weeks or months of treatment delay.
This post breaks down how step therapy actually works, what the major payers require, and what proper failure documentation looks like. It's the kind of groundwork that separates a first-pass approval from a cycle of denials and appeals.
What Step Therapy Actually Means
Step therapy — sometimes called fail-first — requires patients to try lower-cost treatments before a payer will authorize a biologic. The logic is cost containment: biologics for rheumatoid arthritis can run $25,000 to $50,000 per year. A generic DMARD costs a fraction of that.
Payers build step therapy requirements into their formulary policies. Before they'll cover a TNF inhibitor, they want documentation that the patient tried methotrexate, hydroxychloroquine, or another conventional DMARD for a defined period — and that it didn't work or wasn't tolerated.
The problem is that "didn't work" and "defined period" are payer-specific. That's where things get complicated.
Medicare and Medicare Advantage
Traditional Medicare Part B covers biologics administered in office (like infliximab infusions) under a different framework than Part D drugs. For Part B biologics, the step therapy rules are set by local coverage determinations, which vary by MAC jurisdiction.
Medicare Advantage plans are where step therapy hits hardest. As of 2023, CMS allows MA plans to apply step therapy to Part B biologics — and many do. The specific requirements vary by plan, but most follow patterns similar to commercial payer policies for the same indications.
For RA, typical Medicare Advantage step therapy sequences include at least one conventional DMARD (usually methotrexate) tried for 3 to 6 months with documented inadequate response. Some plans require two conventional DMARDs. CMS publishes MAC-specific LCDs for most biologic categories — these are the definitive source for what each jurisdiction requires.
UnitedHealthcare
UnitedHealthcare is the largest commercial payer in the US, and their step therapy requirements are detailed and condition-specific.
For rheumatoid arthritis biologics, United typically requires a minimum of 3 months of methotrexate at an adequate dose (usually 15-25mg/week), with documented laboratory monitoring showing the patient was actually on the drug at therapeutic levels. A note that says "patient tried methotrexate" without dose, duration, and documented response won't clear their criteria.
For psoriasis, United generally requires topical therapy failure plus phototherapy trial or documented contraindication before authorizing IL-17 or IL-23 inhibitors. The word "documented" is doing a lot of work there — the contraindication has to be in the chart, not just asserted in the PA letter.
For Crohn's disease, United's standard sequence runs through conventional therapy (aminosalicylates for mild disease, corticosteroids, then immunomodulators like azathioprine or 6-MP) before authorizing a biologic. Documented steroid dependence can sometimes accelerate the path.
Aetna
Aetna publishes its clinical policy bulletins online, which makes them more transparent than some payers — but also means their reviewers will hold you to exactly what's in the bulletin. Reading the CPB for your specific drug and indication before submitting is not optional; it's table stakes.
Aetna's RA policy requires methotrexate trial with documented inadequate response after at least 3 months at an adequate dose, or a documented contraindication. For psoriatic arthritis, they require at least one DMARD failure before authorizing a biologic, though the DMARD doesn't have to be methotrexate.
One notable Aetna requirement: they often want documentation that the patient's disease remained active despite treatment, not just that the medication was prescribed. Lab values, disease activity scores, or provider notes documenting ongoing symptoms while on therapy strengthen the submission considerably.
Cigna
Cigna's coverage policies — called medical coverage policies — follow similar step therapy logic but with some differences in duration requirements. For RA biologics, Cigna typically requires 3 months of DMARD therapy, comparable to United and Aetna. Where Cigna sometimes diverges is in how strictly they apply this to combination DMARD therapy.
For biologic-naive patients with moderate-to-severe RA, Cigna may accept DMARD combination therapy (methotrexate plus hydroxychloroquine, for instance) as the required prior step rather than methotrexate monotherapy alone. This can matter when a patient has already been managed on a combination regimen.
Cigna's psoriasis policies generally require body surface area documentation alongside step therapy history. BSA less than 10% typically won't qualify for a biologic regardless of what prior treatments were tried — the severity threshold is separate from the step therapy requirement.
Blue Cross Blue Shield
BCBS plans are federated — each state's plan sets its own policies, so BCBS Illinois and BCBS California may have meaningfully different step therapy requirements for the same drug. Checking the specific local plan's coverage policy is essential.
That said, most BCBS plans follow the general DMARD-first framework for RA biologics, with 3-month minimum durations. For Crohn's disease, many BCBS plans are slightly more aggressive about requiring both a thiopurine and biologic-naive status before authorizing TNF inhibitors, compared to some other commercial payers.
Common Step Therapy Sequences by Condition
Rheumatoid Arthritis
- Step 1: Methotrexate at adequate dose (15-25mg/week) for minimum 3 months
- Step 2: May require second DMARD (hydroxychloroquine, sulfasalazine, or leflunomide) at some plans
- Step 3: TNF inhibitor (adalimumab, etanercept, certolizumab) — then IL-6 or JAK inhibitors
- Exception pathway: seronegative disease, MTX contraindication, rapid disease progression
Plaque Psoriasis
- Step 1: Topical therapies (corticosteroids, vitamin D analogs, retinoids) for mild-moderate disease
- Step 2: Phototherapy (nbUVB or PUVA) trial or documented contraindication
- Step 3: Conventional systemic (methotrexate, acitretin, cyclosporine)
- Step 4: IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (risankizumab, guselkumab), or TNF inhibitors
Crohn's Disease
- Step 1: Corticosteroids for acute disease; documented steroid dependence or inability to taper
- Step 2: Immunomodulator (azathioprine, 6-mercaptopurine, or methotrexate) — minimum 3 to 6 months
- Step 3: TNF inhibitor (infliximab, adalimumab, certolizumab pegol)
- Exception: fistulizing disease, steroid-refractory acute disease may bypass steps
How to Document Failure Properly
This is where most submissions fall apart. Documenting that a patient "failed" a prior therapy requires more than noting the medication was prescribed. Payers want a sequential narrative with specific data points.
For each step therapy drug, your documentation should explicitly include: the drug name and dose, start date and end date (or current status), the reason for discontinuation or the objective evidence of inadequate response, and any monitoring data (labs, disease activity scores) collected during the trial.
Phrases like "patient failed prior biologics" without specifics almost always generate denials. "Patient completed 6-month trial of methotrexate 20mg weekly with stable MTX polyglutamate levels; DAS28 remained 5.6 at week 24; discontinued due to inadequate response" gives the reviewer everything they need to check the box.
Exception Criteria: When You Can Skip a Step
Every major payer has exception pathways — clinical situations where the step therapy requirement can be bypassed. The key is documenting the exception explicitly, not just assuming the reviewer will infer it.
Common exception criteria accepted by most payers include: documented contraindication to the required step therapy drug (hepatotoxicity risk with MTX in patients with liver disease, for instance), prior adverse reaction with objective documentation, rapid disease progression requiring urgent treatment, and clinical urgency where the delay of step therapy would cause irreversible harm.
If your patient has a legitimate contraindication, state it precisely: "Methotrexate is contraindicated due to patient's documented hepatic fibrosis (stage F2, confirmed on biopsy dated [month/year])." That's a documentable exception. "Patient cannot take methotrexate" is not.
The Payer Research Problem
Keeping current on step therapy requirements for 5 major payers across 6 common biologic indications is not a realistic ask for a busy rheumatology or GI practice. Policies update quarterly. New biosimilar options shift the step sequences. Medicare Advantage plans change their requirements at open enrollment.
This is precisely what Luma was built to handle. The platform researches payer-specific step therapy requirements in real time for each submission — pulling the current policy for that payer, that drug, and that indication — so the documentation addresses exactly what the reviewer is checking against. No more submitting against a policy that changed six months ago.
The AMA's 2023 prior authorization survey found that 94% of physicians reported care delays due to PA requirements, with biologics among the most affected drug categories. Step therapy documentation failures are a significant driver. Getting this right the first time is worth the investment.
Sources:
1. CMS Medicare Coverage Database — cms.gov/medicare-coverage-database
2. AMA 2023 Prior Authorization Survey — ama-assn.org
3. Aetna Clinical Policy Bulletins — aetna.com
4. ACR Clinical Practice Guidelines — Rheumatoid Arthritis — rheumatology.org
5. AMCP — Step Therapy Policy Analysis — amcp.org